Patents by Inventor Ulf Brueggemeier
Ulf Brueggemeier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7776922Abstract: The invention relates to substituted [(phenylethanoyl)amino]benzamides and methods for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of inflammatory disorders such as, for example, cutaneous, respiratory tract and cardiovascular disorders such as, for example, arteriosclerosis and coronary heart disease.Type: GrantFiled: November 17, 2005Date of Patent: August 17, 2010Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Ulf Brüggemeier, Petros Gatsios, Mark Meininghaus, Leila Telan, Elisabeth Woltering, Martina Wuttke, Hartmut Beck, Nils Griebenow, Frank Süβmeier, Niels Svenstrup, Axel Kretschmer, Marcus Bauser, Johannes Köbberling, Wahed Moradi, Siegfried Zaiss, Claudia Hirth-Dietrich, Barbara Albrecht
-
Publication number: 20100104501Abstract: The invention provides PRSS23, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRSS23 as well as pharmaceutical compositions comprising such compounds. The invention also provides PRSS23 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.Type: ApplicationFiled: October 2, 2007Publication date: April 29, 2010Inventors: Stefan Golz, Holger Summer, Andreas Geerts, Ulf Brüggemeier, Barbara Albrecht, Martina Klein, Sonja Steppan, Peter Ellinghaus, Donatella D'urso, Michael Seewald, Hendrik Milting
-
Publication number: 20100028264Abstract: The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.Type: ApplicationFiled: October 2, 2007Publication date: February 4, 2010Inventors: Stefan Golz, Holger Summer, Andreas Geerts, Ulf Brüggemeier, Barbara Albrecht-Küpper, Martina Klein, Sonja Steppan, Peter Ellinghaus, Donatella D'Urso, Michael Seewald, Hendrik Milting
-
Publication number: 20090311242Abstract: The invention provides a human 5HT2a which is associated with the cardiovascular diseases, respiratory diseases, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, respiratory diseases, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of 5HT2a as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: July 18, 2005Publication date: December 17, 2009Applicant: BAYER HEALTHCARE AGInventors: Stefan Golz, Ulf Brüggemeier, Andreas Geerts
-
Publication number: 20090312381Abstract: The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.Type: ApplicationFiled: May 21, 2007Publication date: December 17, 2009Applicant: BAYER HEALTHCARE AGInventors: Heinrich Meier, Eckhard Bender, Ulf Brüggemeier, Ingo Flamme, Dagmar Karthaus, Peter Kolkhof, Daniel Meibom, Dirk Schneider, Verena Voehringer, Chantal Fürstner, Jörg Keldenich, Dieter Lang, Elisabeth Pook, Carsten Schmeck
-
Patent number: 7491550Abstract: The invention provides a human NMU2 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NMU2 as well as pharmaceutical compositions comprising such compounds.Type: GrantFiled: May 14, 2003Date of Patent: February 17, 2009Assignee: Bayer Healthcare AGInventors: Stefan Golz, Ulf Brüggemeier, Andreas Geerts
-
Patent number: 7465548Abstract: The invention provides a human HM74a which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, urological diseases, respiratory diseases and gastroenterological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, urological diseases, respiratory diseases and gastroenterological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of HM74a as well as pharmaceutical compositions comprising such compounds.Type: GrantFiled: February 5, 2004Date of Patent: December 16, 2008Assignee: Bayer Healthcare AGInventors: Stefan Golz, Ulf Brüggemeier, Holger Summer
-
Patent number: 7338781Abstract: The present invention is directed to a polynucleotide sequence of a novel organic anion transporting (OAT)-like protein UST3-likel. More particularly, the present invention provides a polynucleotide sequence comprising the nucleic acid sequence SEQ ID NO: 1 or nucleic acid sequences that hybridize to SEQ ID NO: 1 or its complimentary strand. The invention also provides the human UST3-LIKE1 associated with the gastrointestinal and liver diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders and cardiovascular diseases as a result of relative quantification of the mRNA distribution in different human tissues by expression profiling. The invention also provides assays for the identification of compounds useful for the modulation of said diseases.Type: GrantFiled: March 4, 2004Date of Patent: March 4, 2008Assignee: Bayer HealthCare AGInventors: Stefan Golz, Ulf Brüggemeier, Andreas Geerts
-
Patent number: 7220824Abstract: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and ?v?3 integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.Type: GrantFiled: August 28, 2000Date of Patent: May 22, 2007Assignee: Bayer AktiengesellschaftInventors: Hans-Georg Lerchen, Jörg Baumgarten, Ulf Brüggemeier, Markus Albers, Andreas Schoop, Thomas-J. Schulze
-
Publication number: 20060234240Abstract: The invention provides a human 5-HT1F which is associated with the hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of 5-HT1F as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: February 4, 2004Publication date: October 19, 2006Applicant: Bayer HealthCare AGInventors: Stefan Golz, Ulf Brüggemeier, Andreas Geerts
-
Patent number: 7094911Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1) wherein R1, R2, U, V, A, B, W, R3, C and R4 have the meaning as defined in the claims.Type: GrantFiled: October 31, 2002Date of Patent: August 22, 2006Assignee: Bayer AktiengesellschaftInventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Härter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jörg Keldenich, Ulf Brueggemeier, Klemens Lustig
-
Publication number: 20040030132Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases.Type: ApplicationFiled: October 31, 2002Publication date: February 12, 2004Inventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Harter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jorg Keldenich, Ulf Brueggemeier, Klemens Lustig
-
Patent number: 6677360Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1) wherein R1, R2, U, V, A, B, W, R3, C and R4 have the meaning as defined in the claims.Type: GrantFiled: April 6, 2001Date of Patent: January 13, 2004Assignee: Bayer AktiengesellschaftInventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Härter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jörg Keldenich, Ulf Brueggemeier, Klemens Lustig
-
Patent number: 6589972Abstract: The present invention relates to compounds of the general formula (1) wherein R4 is —SO2R4′, —COOR4″, —COR4′, —CONR4′2 or —CSNR4′2; R4′ is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; R4″ is a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; L is a sulphonamide, amide, ether, ester, keto, urea, thioether, sulphoxide or sulphone unit optionally extended by one or two methylene groups; and X is N, O or S; and their physiologically acceptable salts and stereoisomers.Type: GrantFiled: May 30, 2001Date of Patent: July 8, 2003Assignee: Bayer AktiengesellschaftInventors: Andreas Schoop, Gerhard Mueller, Ulf Brueggemeier, Delf Schmidt, Beatrix Stelte-Ludwig, Joerg Keldenich
-
Patent number: 6495545Abstract: The present invention relates to compounds of general formula (I) and their preparation and use for the production of pharmaceuticals, and pharmaceuticals comprising these compounds.Type: GrantFiled: June 12, 2001Date of Patent: December 17, 2002Assignee: Bayer AktiengesellschaftInventors: Klaus Urbahns, Delf Schmidt, Ulf Brüggemeier, Christoph Gerdes, Beatrix Stelte-Ludwig, Jörg Keldenich, Elke Stahl
-
Patent number: 6420396Abstract: The present invention relates to 2-Mesitylsulfonylamino-3-{3′[(pyridinylamino)methyl][1,1-biphenyl]-4-yl}propanoic acid, pharmaceutical compositions thereof, their preparation, their use in the treatment of cancer, arteriosclerosis, restenosis, osteolytic disorders, ophthalmic disorders, and their use as integrin antagonists.Type: GrantFiled: December 15, 1999Date of Patent: July 16, 2002Assignee: Beiersdorf AGInventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Härter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jörg Keldenich, Ulf Brueggemeier, Klemens Lustig
-
Publication number: 20020016461Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases.Type: ApplicationFiled: April 6, 2001Publication date: February 7, 2002Inventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Harter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jorg Keldenich, Ulf Brueggemeier, Klemens Lustig
-
Patent number: 6339083Abstract: The present invention relates to compounds of the general formula (I): and their preparation and use for the production of pharmaceuticals, and pharmaceuticals comprising these compounds.Type: GrantFiled: December 14, 1998Date of Patent: January 15, 2002Assignee: Bayer AktiengesellschaftInventors: Klaus Urbahns, Delf Schmidt, Ulf Brueggemeier, Christoph Gerdes, Beatrix Stelte-Ludwig, Jörg Keldenich, Elke Stahl
-
Publication number: 20010031788Abstract: The present invention relates to compounds of the general formula (1) 1Type: ApplicationFiled: May 30, 2001Publication date: October 18, 2001Inventors: Andreas Schoop, Gerhard Mueller, Ulf Brueggemeier, Delf Schmidt, Beatrix Stelte-Ludwig, Joerg Keldenich
-
Patent number: 6291503Abstract: The present invention relates to compounds of the general formula (1) wherein R4 is —SO2R4, —COOR4′, —COR4′, —CONR4′2 or —CSNR4′2; R4′ is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; R4″ is a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; L is a sulphonamide, amide, ether, ester, keto, urea, thioether, sulphoxide or sulphone unit optionally extended by one or two methylene groups; and X is N, O or S; and their physiologically acceptable salts and stereoisomers.Type: GrantFiled: January 15, 1999Date of Patent: September 18, 2001Assignee: Bayer AktiengesellschaftInventors: Andreas Schoop, Gerhard Mueller, Ulf Brueggemeier, Delf Schmidt, Beatrix Stelte-Ludwig, Joerg Keldenich